Tucson, AZ, United States of America

Eli Chapman

This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignees: Indiana University, The University of Arizona. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eli Chapman. Retrieved from https://idiyas.com/inventor/eli-chapman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eli Chapman: Innovator in Antibiotic Resistance Solutions

Introduction

Eli Chapman is a notable inventor based in Tucson, AZ (US). He has made significant contributions to the field of antibiotic research, particularly in developing novel compounds to combat bacterial resistance.

Latest Patents

Eli Chapman holds a patent for "Analogs of nitrofuran antibiotics to combat resistance." This patent focuses on novel compounds and methods for killing or inhibiting the growth of bacteria, addressing a critical issue in modern medicine.

Career Highlights

Throughout his career, Eli has worked with prestigious institutions such as Indiana University and The University of Arizona. His work has been instrumental in advancing the understanding and treatment of antibiotic resistance.

Collaborations

Eli has collaborated with Steven Johnson, further enhancing the impact of his research and innovations in the field.

Conclusion

Eli Chapman is a dedicated inventor whose work in antibiotic resistance is paving the way for future advancements in medical treatments. His contributions are vital in the ongoing battle against bacterial infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…